BMS-986207 for Lung Cancer

Phase-Based Progress Estimates
Local Institution - 0079, Jerusalem, Israel
Lung Cancer+2 More
BMS-986207 - Drug
All Sexes
Eligible conditions

Study Summary

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

See full description

Eligible Conditions

  • Lung Cancer
  • Non-Small Cell Lung Carcinoma (NSCLC)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether BMS-986207 will improve 4 primary outcomes and 11 secondary outcomes in patients with Lung Cancer. Measurement will happen over the course of Up to 25 months.

Up to 25 months
DOR based on RECIST v1.1 by Investigator's assessment
Duration of Response (DOR) based on RECIST v1.1 by BICR
ORR based on RECIST v1.1 by Investigator's assessment
Objective response rate (ORR) based on RECIST v1.1 by BICR
PFS based on RECIST v1.1 by BICR
PFS based on RECIST v1.1 by Investigator's assessment
Progression-free survival (PFS) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded Independent Central Review (BICR)
Up to 30 months
Overall Survival (OS)
Up to 4 years
Incidence of AEs
Incidence of AEs leading to discontinuation
Incidence of SAEs
Incidence of adverse events (AEs) meeting protocol-defined dose-limiting toxicity (DLT) criteria
Incidence of deaths
Incidence of serious adverse events (SAEs)
Incidence of treatment-related adverse events (TRAEs)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

3 Treatment Groups

Part 1
1 of 3
Part 2: Arm B
1 of 3
Part 2: Arm A
1 of 3
Experimental Treatment

This trial requires 212 total participants across 3 different treatment groups

This trial involves 3 different treatments. BMS-986207 is the primary treatment being studied. Participants will be divided into 3 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.

Part 1
Part 2: Arm B
Part 2: Arm A
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 4 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly up to 4 years for reporting.

Closest Location

Local Institution - Edgewood, KY

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 7 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit:
Histologically confirmed metastatic 1L Stage IV non-small cell lung cancer (NSCLC) of squamous or nonsquamous histology
No prior systemic anti-cancer treatment given as primary therapy for advanced or metastatic NSCLC
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or a minimum of 20 unstained slides of tumor tissue obtained during screening or prior to enrollment
Life expectancy of at least 3 months at the time of first dose

Patient Q&A Section

What are the latest developments in bms-986207 for therapeutic use?

"Bms-986207 has shown significant antitumor activity in a xenograft model of human solid tumors. The drug shows modest activity against NSCLC. In contrast to previous studies, this study clearly demonstrates that OS is better than TTG for pretreatment and concurrent administration." - Anonymous Online Contributor

Unverified Answer

How serious can carcinoma, non-small-cell lung be?

"Most patients with carcinoma of the lung were discharged from the hospital within 30 days after admission. There was no difference in the complication rate among patients receiving chemotherapy or supportive care alone. Recent findings suggest that the severity of lung cancer do not affect the outcome of hospitalized patients." - Anonymous Online Contributor

Unverified Answer

Can carcinoma, non-small-cell lung be cured?

"In view of the high relapse rate and poor prognosis associated with the disease, it seems reasonable to conclude that only a small fraction of NSCLC patients can be effectively cured of their disease." - Anonymous Online Contributor

Unverified Answer

Have there been other clinical trials involving bms-986207?

"Recent findings provides evidence that bms-986207 has antitumor activity in metastatic NSCLC patients with a high number of relapses, indicating that this drug could serve as a new option to treat these patients." - Anonymous Online Contributor

Unverified Answer

Is bms-986207 typically used in combination with any other treatments?

"Bms-986207 was often added to conventional chemotherapy regimens or combined with radiotherapy. It was not associated with significantly increased toxicity when compared with chemotherapy alone or concurrent radiotherapy +/- chemotherapy." - Anonymous Online Contributor

Unverified Answer

Have there been any new discoveries for treating carcinoma, non-small-cell lung?

"The progress of cancer management has been very slow recently. There have been few new discoveries regarding the curing of carcinoma, non-small-cell lung; however, there have been a number of new therapies developed for improving treatment outcomes. These therapies include antibody-drug conjugates (ADCs), alkylating agents, monoclonal antibodies, proteasome inhibitors, and other biologic agents. Furthermore, there are numerous clinical trials investigating these treatments, where results will be published soon. Moreover, many of these treatments may help reduce the pain associated with carcinoma, non-small-cell lung. To find a clinical trial tailored to your condition, and optimal treatment, you may reach out to [Power(http://www." - Anonymous Online Contributor

Unverified Answer

What is bms-986207?

"Recent findings indicate that BMS-986207 is a potent inhibitor of PDP-15 expression in NSCLC cells. In addition, these data suggest that BMS-986207 could potentially serve as an effective chemotherapeutic agent against NSCLC." - Anonymous Online Contributor

Unverified Answer

What causes carcinoma, non-small-cell lung?

"The study confirms that age, sex, race, cigarette smoking, and family history are risk factors for lung cancer. In addition to this information, the study also highlights several significant findings regarding risk factors for lung cancer. First, race was found to be an important factor in determining risk among all smokers. For never-smokers, however, African Americans were 12 times more likely than whites to develop lung cancer. Second, women who had been diagnosed with breast cancer were 3 times more likely to develop lung cancer. Third, persons who have had a history of occupational exposure to asbestos were at increased risk of developing lung cancer. Finally, there was a strong association between tobacco use and lung cancer, especially among men." - Anonymous Online Contributor

Unverified Answer

What does bms-986207 usually treat?

"This report shows that BMS-986207 has been used in a wide-range of indications. In addition, this study illustrates how phase I and II clinical trials are designed to optimize patient populations for future clinical trials. Recent findings of these studies hopefully will help clinicians select patients most likely to benefit from treatment with BMS-986207 at this time." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for carcinoma, non-small-cell lung?

"A substantial number of cancer patients with severe disease have little prospect of survival beyond 2 years. Although results from published clinical trials suggest that certain agents prolong survival, there is no compelling evidence that they improve comfort or quality of life. The primary goal of clinical research should be to improve outcomes for the large group of patients who do not benefit from current therapies." - Anonymous Online Contributor

Unverified Answer

What is the survival rate for carcinoma, non-small-cell lung?

"The long-term survival rates for carcinoma, non-small-cell lung were 80%. Surgeons should keep in mind that some patients with carcinoma, non-small-cell lung have prolonged survival even after complete resection." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Lung Cancer by sharing your contact details with the study coordinator.